Status:
COMPLETED
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
10-75 years
Brief Summary
This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clini...
Eligibility Criteria
Inclusion
- Type 1 and type 2 diabetics who are treated with human premix insulin (the selection of the subjects will be at the discretion of the individual physician).
Exclusion
- Subjects currently being treated with biphasic insulin aspart 30
- Subjects who were previously enrolled in this study
- Subjects with a hypersensitivity to biphasic insulin aspart 30 or to any of the excipients
- Women who are pregnant or have the intention of becoming pregnant within next 6 months
- Children below 10 years of age
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
942 Patients enrolled
Trial Details
Trial ID
NCT00675493
Start Date
May 1 2008
End Date
January 1 2009
Last Update
February 19 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bucharest, Romania, 010031